Zelgen(SH:688266) Xin Lang Cai Jing·2025-08-28 06:22Core Viewpoint - Zai Jian Pharmaceutical experienced a 5.01% decline in stock price, reaching 97.36 CNY per share, with a total market capitalization of 25.772 billion CNY as of August 28 [1] Company Overview - Suzhou Zai Jian Biopharmaceutical Co., Ltd. was established on March 18, 2009, and went public on January 23, 2020. The company focuses on the research, development, production, and sales of chemical and biological new drugs [1] - The main revenue composition of the company is 99.97% from pharmaceuticals, 0.02% from pharmaceutical intermediates and raw materials, and 0.00% from asset leasing [1] Fund Holdings - Huaxi Fund has a significant holding in Zai Jian Pharmaceutical, with the Huaxi Research Selected Mixed Fund (020444) holding 62,100 shares, accounting for 5.72% of the fund's net value, ranking as the tenth largest holding [2] - The fund has reported a floating loss of approximately 319,100 CNY as of the latest update [2] - The Huaxi Research Selected Mixed Fund was established on December 28, 2023, with a current size of 117 million CNY and has achieved a year-to-date return of 22.25%, ranking 3067 out of 8191 in its category [2] - Over the past year, the fund has generated a return of 53.02%, ranking 2083 out of 7967 in its category, and has an overall return of 18.01% since inception [2] - The fund manager, Wu Wenqing, has a tenure of 11 years and 249 days, with the best fund return during his tenure being 96.36% and the worst being -21.1% [2]